CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17%

CureVac and GSK have picked the mRNA approach that will advance in the clinic for flu and COVID-19 after seeing phase 1 data on a handful of candidates. While analysts were happy to see the win, they were skeptical of the lack of updated variant data and limited population read-out—even going so far as to call the disclosure “half-baked.”